Wnt Signaling as a Therapeutic Target in Cancer and Metastasis
Morgan, Richard; Ankrah, R.; El-Tanani, S.; Patterson, Laurence H.; Loadman, Paul M.; Rudland, P.S.; El-Tanani, Mohamed (2017)
Paul Loadman
Professor
- Area
- Institute of Cancer Therapeutics
- Faculty of Life Sciences
- Phone
Biography
Pharmacokinetics and tumour drug metabolism of anti-cancer drugs
Professor Paul Loadman heads the drug metabolism team at the Institute of Cancer Therapeutics, University of Bradford and has >40years experience studying the pharmacokinetics and metabolism of anti-cancer drugs. The team in Bradford have studied a wide range of clinically available and novel small molecules including antimetabolites, platinating and alkylating agents, peptides and antivascular compounds. Prof Loadman is actively involved in the design, analysis and reporting of pre-clinical and clinical pharmacokinetic studies and acts as a pharmacokinetic and drug metabolism consultant for numerous pharmaceutical and biotechnology companies. Together with Prof Twelves (Clinical Director,) the DMPK team have established a Quality Management System within the ICT which has enabled a strong involvement in the pharmacokinetic monitoring of small molecules in major clinical trials. Other major clinical collaborations include with Professor Mark Hull at the University of Leeds (The seAFOod Polyp Prevention Trial, www.seafood-trial.co.uk) where the laboratory in Bradford are analyzing a series of bioactive lipid mediators such as ω-3 PUFAs, resolvin E1 and PGE-M in plasma, urine, erythrocytes and rectal mucosa in order to gain insights into the mechanism of action of EPA and aspirin.
Research
- Pharmacokinetics and tumour drug metabolism of anti cancer drugs
- Matrix metalloproteinases as targets for tumour-selective delivery of anticancer therapeutics
- Drug delivery and prodrug design
- Novel advances in analytical techniques. HPLC, GC, CE and LC/MS/MS
- Drug interactions both in vitro and in vivo
Professional activities
- University of Bradford - PhD
- Royal Society of Biology , Royal Society of Biology
- Drug Metabolism Discussion Group (DMDG), Drug Metabolism Discussion Group (DMDG)
- Pharmacokinetics and Molecular Mechanisms (PAMM) Group, Pharmacokinetics and Molecular Mechanisms (PAMM) Group
- European Association for Cancer Research , European Association for Cancer Research
- American Association for Cancer Research , American Association for Cancer Research
- British Association for Cancer Research , British Association for Cancer Research
Publications
-
-
Practical aspects of pharmacokinetics and pharmacodynamics
Loadman, Paul M. (2015)
-
Development of tumour selective and endoprotease-activated anticancer therapeutics.
Gill, Jason H.; Loadman, Paul M. (2008)
-
Development of tumour-selective and endoprotease-activated anticancer therapeutics
Gill J.;Loadman P. (2008) The Cancer Degradome: Proteases and Cancer Biology. 853-876.
-
Hypoxia-Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment-Resistant Cancer Cells
Francis M. Barnieh,* Goreti Ribeiro Morais, Paul M. Loadman, Robert A. Falconer, and Sherif F. El-Khamisy (2024) Advanced Science. 2403831, 1-20.
-
Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists
Adam Throup;Manar Saleh Zraikat;Andrew Gordon;Shohreh Jafarinejad Soumehsaraei;Kathrin D Haase;Laurence H Patterson;Patricia A Cooper;Katherine Hanlon;Paul M Loadman;Mark Sutherland;Steven D Shnyder;Helen M Sheldrake (2024) Rsc Medicinal Chemistry.
-
APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps
Ge SunJohn, R Davies ,Tracey Mell, Mark Harland, Rasha M H Saleh, Amanda D Race, Paul M Loadman, Elizabeth A Williams, Anne Marie Minihane, Mark A Hull (2024) Prostaglandins Leukotrienes and Essential Fatty Acids. 201
-
Maleimide-thiol linkages alter the biodistribution of therapeutic microbubbles compared to biotin-avidin while preserving parity in tumoral drug delivery
Nicola Ingram, Radwa H. Abou-Saleh, Amanda Race, Paul M. Loadman, Richard Bushby, Stephen D. Evans, P. Louise Coletta (2024) Pharmaceutics. 16
-
The relationship between dietary and supplemental n-3 HUFA intake, blood and tissue n-3 HUFA levels, and colorectal polyp recurrence: A secondary analysis of the seAFOod polyp prevention trial
Ge Sun, Harriett Fuller ,Hayley Fenton ,Amanda D. Race ,Amy Downing , Colin J. Rees,Louise C. Brown ,Paul M. Loadman , Elizabeth A. Williams , Mark A. Hull (2024) Journal of Nutrition.
-
Cancer-specificglycosylationofCD13impactsits detectionandactivityinpreclinicalcancertissues
Francis M. Barnieh,1,4,* Sebastian P. Galuska,2 Paul M. Loadman,1 Simon Ward,3 Robert A. Falconer,1 and Sherif F. El-Khamisy1 (2023) Iscience., 1-13.
-
The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial
Ge Sun, Harriett Fuller, Hayley Fenton, Amanda D. Race, Amy Downing, Elizabeth A. Williams, Colin J. Rees, Louise C. Brown, Paul M. Loadman, Mark A. Hull (2023) International Journal of Cancer. 00
-
Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use.
Downing A;Fenton H;Nickerson C;Loadman PM;Williams EA;Rees CJ;Brown LC;Morris EJA;Hull MA; (2023) Alimentary Pharmacology and Therapeutics.
-
Polymorphisms in Cyclooxygenase, Lipoxygenase and TP53 genes predict colorectal polyp risk reduction by aspirin in the seAFOod polyp prevention tria
John R Davies, Tracey Mell, Harriett Fuller, Mark Harland, Rasha N M Saleh, Amanda D Race, Colin J Rees, Louise C Brown, Paul M Loadman, Amy Downing, Anne Marie Minihane, Elizabeth A Williams Mark A Hull (2023) Cancer Prevention Research. september
-
Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial.
Fuller H;Race AD;Fenton H;Burke L;Downing A;Williams EA;Rees CJ;Brown LC;Loadman PM;Hull MA; (2023) Prostaglandins Leukotrienes and Essential Fatty Acids. 192
-
Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol
Mark A Hull , Pei Loo Ow, Sharon Ruddock, Tim Brend, Alexandra F Smith, Helen Marshall, Mingyang Song, Andrew T Chan, Wendy S Garrett, Omer Yilmaz, David A Drew, Fiona Collinson, Andrew J Cockbain, Robert Jones, Paul M Loadman , Peter S Hall, Catherine Moriarty, David A Cairns, Giles J Toogood (2023) BMJ Open. 13
-
A Single Short 'Tone Burst' Results in Optimal Drug Delivery to Tumours Using Ultrasound-Triggered Therapeutic Microbubbles.
Ingram N;McVeigh LE;Abou-Saleh RH;Batchelor DVB;Loadman PM;McLaughlan JR;Markham AF;Evans SD;Coletta PL; (2022) Pharmaceutics. 14
-
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler S;Ramírez-Suástegui C;Li Y;King E;Chudley L;Thomas J;Wood O;von Witzleben A;Jeffrey D;McCann K;Simon H;Mondal M;Wang A;Dicker M;Lopez-Guadamillas E;Chou TF;Dobbs NA;Essame L;Acton G;Kelly F;Halbert G;Sacco JJ;Schache AG;Shaw R;McCaul JA;Paterson C;Davies JH;Brennan PA;Singh RP;Loadman PM;Wilson W;Hackshaw A;Seumois G;Okkenhaug K;Thomas GJ;Jones TM;Ay F;Friberg G;Kronenberg M;Vanhaesebroeck B;Vijayanand P;Ottensmeier CH; (2022) Nature. 605
-
The role of MT1-MMP in the progression and metastasis of osteosarcoma
Spencer, H.L.M.; Shnyder, S.D.; Loadman, P.M.; Falconer, R.A. (2022) Journal of Cancer Metastasis and Treatment. 9
-
Targeted delivery of a colchicine analogue provides synergy with ATR inhibition in cancer cells
(2022) Biochemical Pharmacology.
-
Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects
Ian S. Miller, Sonja Khan, Liam P. Shiels, Sudipto Das, Alice C. O' Farrell, Kate Connor, Adam Lafferty, Bruce Moran, Claudio Isella, Paul Loadman, Emer Conroy, Susan Cohrs, Roger Schibli, Robert S. Kerbel, William M. Gallagher, Elisabetta Marangoni, Kathleen Bennett, Darran P. O' Connor, Róisín M. Dwyer, Annette T. Byrne (2022) Cancer Medicine. 11
-
Progress towards a clinically-successful ATR inhibitor for cancer therapy
Barnieh, F.M.; Loadman, P.M.; Falconer, R.A. (2021) Current Research in Pharmacology and Drug Discovery. 2
-
An assay for quantitative analysis of polysialic acid expression in cancer cells
Guo, X.; Elkashef, S.M.; Patel, A.; Ribeiro Morais, G.; Shnyder S.D.; Loadman, P.M.; Patterson, L.H.; Falconer, R.A. (2021) Carbohydrate Polymers. 259
-
Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, Combretastatin A4.
Charalambous A;Mico V;McVeigh LE;Marston G;Ingram N;Volpato M;Peyman SA;McLaughlan JR;Wierzbicki A;Loadman P;Bushby RJ;Markham AF;Evans SD;Coletta PL; (2021) Nanomedicine: Nanotechnology, Biology, and Medicine.
-
How can the potential of the duocarmycins be unlocked for cancer therapy?
Jukes Z;Morais GR;Loadman PM;Pors K; (2021) Drug Discovery Today. 26
-
Luminal bioavailability in the distal small intestine and changes to the ileal microbiome after oral administration of omega-3 polyunsaturated fatty acids
Gael Nana, Henry Watson, Suparna Mitra, Caroline Young, Henry M Wood, Sarah L Perry, Amanda D Race, Philip Quirke, Giles J Toogood, Paul M Loadman, Mark A Hull (2021) Journal of Nutrition. 151, 2142-2152.
-
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds
Natalia Ortuzar, Kersti Karu, Daniela Presa, Goreti R. Morais, Helen M. Sheldrake, Steve D. Shnyder, Francis M. Barnieh, Paul M. Loadman, Laurence H. Patterson, Klaus Pors, Mark Searcey (2021) BIOORGANIC & MEDICINAL CHEMISTRY. 40
-
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer.
Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; (2021) Scientific Reports. 11
-
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?
Barnieh FM;Loadman PM;Falconer RA; (2021) Biochimica et Biophysica Acta - Reviews on Cancer. 1876
-
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.
Ortuzar N;Karu K;Presa D;Morais GR;Sheldrake HM;Shnyder SD;Barnieh FM;Loadman PM;Patterson LH;Pors K;Searcey M; (2021) Bioorganic and Medicinal Chemistry. 40
-
Cytochrome P450 Binding and Bioactivation of Tumor-targeted Duocarmycin Agents.
Bart AG;Morais G;Vangala VR;Loadman PM;Pors K;Scott EE; (2021) Drug Metabolism And Disposition: The Biological Fate Of Chemicals.
-
An efficient assay for identification and quantitative evaluation of potential polysialyltransferase inhibitors.
Guo X; Malcolm J.R.; Ali M.M.; Ribeiro Morais G; Shnyder S.D.; Loadman P.M.; Patterson L.H.; Falconer R.A. (2020) ANALYST (PRINT). 145, 4512-4521.
-
Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumour drug accumulation and limiting bioavailability and toxicity in normal tissues
Nicola Ingram1*, Laura E. McVeigh1*, Radwa H. Abou-Saleh2,3, Juliana Maynard4, Sally A. Peyman2, James R. McLaughlan5, Michael Fairclough6, Gemma Marston1, Elizabeth M.A. Valleley 1, Jorge L. Jimenez-Macias1, Antonia Charalambous1, William Townley4, Malcolm Haddrick4, Antonia Wierzbicki7, Alexander Wright1, Milène Volpato1, Peter B. Simpson4, Darren E. Treanor1, Neil H. Thomson8, Paul M. Loadman7, Richard J. Bushby2,9, Benjamin R.G. Johnson2, Pamela F. Jones1, Tony Evans1, Steven Freear5, Alexander F. Markham1, Stephen D. Evans2,*, P. Louise Coletta1,* (2020) Theranostics. 10
-
Theranostic nanoparticles enhance the response of glioblastomas to radiation
Wu, W.; Klockow, J.L.; Mohanty, S.; Ku, K.S.; Aghighi, M.; Melemenidis, S.; Chen, Z.; Li, K.; Ribeiro Morais, Goreti; Zhao, N.; Schlegel, J.; Graves, E.E.; Rao, J.; Loadman, Paul M.; Falconer, R.A.; Mukherjee, S.; Chin, F.T.; Daldrup-Link, H.E. (2019) Nanotheranostics. 3, 299-310.
-
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer
Roger M. Phillips, Paul M. Loadman, Guru Reddy (2019) Cancer Chemotherapy and Pharmacology. 83
-
Recent advances in the analysis of polysialic acid from complex biological systems
Xiaoxiao Guo, Sara M. Elkashef, Mark Sutherland, Paul M. Loadman and Robert A. Falconer (2019) Carbohydrate Polymers. 16
-
Cellular uptake and efflux of palbociclib in vitro in single cell and spheroid models.
Jove M;Spencer JA;Hubbard ME;Holden EC;O'Dea RD;Brook BS;Phillips RM;Smye SW;Loadman P;Twelves CJ; (2019) Journal of Pharmacology and Experimental Therapeutics. 371
-
Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance
Jove, M.; Spencer, Jade A.; Clench, M.; Loadman, Paul M.; Twelves, C. (2019) Critical Reviews in Oncology/Hematology. 141, 153-162.
-
A study of inter-individual variability in the Phase II metabolism of xenobiotics in human skin
Spriggs, S.; Cubberley, R.; Loadman, Paul M.; Sheffield, D.; Wierzbicki, Antonia (2018) Toxicology Letters. 292, 63-72.
-
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial
Hull, M.A.; Sprange, K.; Hepburn, T.; Tan, W.; Shafayat, A.; Rees, C.J.; Clifford, G.; Logan, R.F.; Loadman, Paul M.; Williams, E.A.; Whitham, D.; Montgomery, A.A. (2018) Lancet. 392, 2583-2594.
-
A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
Watson, H.; Mitra, S.; Croden, F.C.; Taylor, M.; Wood, H.M.; Perry, S.L.; Spencer, Jade A.; Quirke, P.; Toogood, G.J.; Lawton, C.L.; Dye, L.; Loadman, Paul M.; Hull, M.A. (2018) Gut. 67, 1974-1983.
-
Structural properties governing drug-plasma protein binding determined by high-performance liquid chromatography method
Kamble, Sharad R.; Loadman, Paul M.; Abraham, M.H.; Liu, Xiangli (2018) Journal of Pharmaceutical and Biomedical Analysis. 149, 16-21.
-
Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting
Falconer, R.A.; Loadman, P.M. (2017) Journal of Cancer Metastasis and Treatment. 3, 315-327.
-
Drug delivery in a tumour cord model: a computational simulation
Hubbard, M.E.; Jove, M.; Loadman, Paul M.; Phillips, Roger M.; Twelves, Christopher J.; Smye, S.W. (2017) Royal Society Open Science. 4
-
A novel theranostic strategy for MMP-14 expressing glioblastomas impacts survival
Mohanty, S.; Chen, Z.; Li, K.; Ribeiro Morais, G.; Klockow, J.; Yerneni, K.; Pasani, L.; Chin, F.T.; Mitra, S.; Cheshier, S.; Chang, E.; Gambhir, S.S.; Rao, J.; Loadman, P.M.; Falconer, R.A.; Daldrup-Link, H.E. (2017) Molecular Cancer Therapeutics. 16, 1909-1921.
-
Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs
Jain, M.; Harburn, J.J.; Gill, J.H.; Loadman, P.M.; Falconer, R.A.; Mooney, C.A.; Cobb, S.L.; Berry, David J. (2017) Journal of Medicinal Chemistry. 60, 4496-4502.
-
A liquid chromatography-tandem mass spectrometry method to measure fatty acids in biological samples
Volpato, Milène; Spencer, Jade A.; Race, Amanda D.; Munarini, A.; Belluzzi, A.; Cockbain, A.; Hull, M.; Loadman, Paul M. (2017) J Chromatography B. 1055, 125-134.
-
An optimised assay for quantitative, high-throughput analysis of polysialyltransferase activity
Elkashef, Sara M.; Sutherland, Mark H.; Patterson, Laurence H.; Loadman, Paul M.; Falconer, Robert A. (2016) ANALYST (PRINT). 141, 5849-5856.
-
Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases
Watson, H.; Cockbain, A.J.; Spencer, Jade A.; Race, Amanda D.; Volpato, Milène; Loadman, Paul M.; Toogood, G.J.; Hull, M.A. (2016) Prostaglandins Leukotrienes and Essential Fatty Acids. 115
-
Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment
Elkashef, Sara M.; Allison, Simon J.; Sadiq, Maria; Basheer, Haneen A.; Ribeiro Morais, Goreti; Loadman, Paul M.; Pors, Klaus; Falconer, Robert A. (2016) Scientific Reports. 6
-
Proteases in cancer drug delivery
Vandooren, J.; Opdenakker, G.; Loadman, Paul M.; Edwards, D.R. (2016) Advanced Drug Delivery Reviews. 97, 144-145.
-
Probing cytochrome P450-mediated activation with a truncated azinomycin analogue
Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus (2015) MedChemComm. 6, 187-191.
-
Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA
Batubara, A.; Carolan, V.A.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Clench, M.R. (2015) Rapid Communications In Mass Spectrometry. 29, 1288-1296.
-
Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity
Gill, Jason H.; Loadman, Paul M.; Shnyder, Steven D.; Cooper, Patricia A.; Atkinson, Jennifer M.; Ribeiro Morais, Goreti; Patterson, Laurence H.; Falconer, Robert A. (2014) Molecular Cancer Therapeutics. 11, 1294-1300.
-
Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota
Piazzi, G.; D'Argenio, G.; Prossomariti, A.; Lembo, V.; Mazzone, G.; Candela, M.; Biagi, E.; Brigidi, P.; Vitaglione, P.; Fogliano, V.; D'Angelo, L.; Fazio, C.; Munarini, A.; Belluzzi, A.; Ceccarelli, C.; Chieco, P.; Balbi, T.; Loadman, Paul M.; Hull, M.A.; Romano, M.; Bazzoli, F.; Ricciardiello, L. (2014) International Journal of Cancer. 135, 204-213.
-
In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog
Wong, C.C.; Periasamy, Nagarajan; Sagineedu, S.R.; Sidik, S.; Sumon, S.H.; Loadman, Paul M.; Phillips, Roger M.; Lajis, N.H.; Stanslas, J. (2014) Investigational New Drugs. 32, 806-814.
-
Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy
Ansari, C.; Tikhomirov, G.A.; Hong, S.H.; Falconer, Robert A.; Loadman, Paul M.; Gill, Jason H.; Castaneda, R.; Hazard, F.K.; Tong, L.; Lenkov, O.D.; Felsher, D.W.; Rao, J.; Daldrup-Link, H.E. (2014) Small. 10, 565-575.
-
Mathematical and computational models of drug transport in tumours
Groh, C.M.; Hubbard, M.E.; Jones, P.F.; Loadman, Paul M.; Periasamy, Nagarajan; Sleeman, B.D.; Smye, S.W.; Twelves, Christopher J.; Phillips, Roger M. (2014) Journal of the Royal Society Interface. 11
-
Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass
Kant, P.; Perry, S.L.; Dexter, S.P.; Race, Amanda D.; Loadman, Paul M. (2014) Bmc Obesity. 22, 202-210.
-
Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid
Cockbain, A.J.; Volpato, Milène; Race, Amanda D.; Munarini, A.; Fazio, C.; Belluzzi, A.; Loadman, Paul M.; Toogood, G.J.; Hull, M.A. (2014) Gut. 63, 1760-1768.
-
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): Study protocol for a randomized controlled trial
Hull M.;Sandell A.;Montgomery A.;Logan R.;Clifford G.;Rees C.;Loadman P.;Whitham D. (2013) Trials. 14
-
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder
Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H. (2013)
-
Identification of Stage-Specific Breast Markers using Quantitative Proteomics
Shaheed, Sadr-ul; Rustogi, Nitin; Scally, Andy J.; Wilson, J.; Thygesen, H.; Loizidou, M.A.; Hadjisavvas, A.; Hanby, A.; Speirs, V.; Loadman, Paul M.; Linforth, R.; Kyriacou, K.; Sutton, Chris W. (2013)
-
Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration
Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. (2013) PLoS ONE. 8
-
A randomised controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) Polyp Prevention Trial
Hull, M.A.; Sandell, A.C.; Montgomery, A.A.; Logan, R.F.A.; Clifford, G.M.; Rees, C.J.; Loadman, Paul M.; Whitham, D. (2013)
-
Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging
Djidja, M-C.; Francese, S.; Claude, E.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Cooper, Patricia A.; Patterson, Laurence H.; Carolan, V.A.; Clench, M.R. (2013)
-
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity
Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus (2013)
-
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins
Travica, S.; Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Johansson, I.; Alandas, Mohammed N.; Sheldrake, Helen M.; Mkrtchian, S.; Patterson, Laurence H.; Ingelman-Sundberg, M. (2013)
-
Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties
Cosentino L.;Redondo-Horcajo M.;Zhao Y.;Santos A.;Chowdury K.;Vinader V.;Abdallah Q.;Abdel-Rahman H.;Fournier-Dit-Chabert J.;Shnyder S.;Loadman P.;Fang W.;Díaz J.;Barasoain I.;Burns P.;Pors K. (2012) Journal of Medicinal Chemistry. 55, 11062-11066.
-
Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation
Fournier-Dit-Chabert J.;Vinader V.;Santos A.;Redondo-Horcajo M.;Dreneau A.;Basak R.;Cosentino L.;Marston G.;Abdel-Rahman H.;Loadman P.;Shnyder S.;Díaz J.;Barasoain I.;Falconer R.;Pors K. (2012) Bioorganic and Medicinal Chemistry Letters. 22, 7693-7696.
-
FGFR1-induced Epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms
Tomlinson D.;Baxter E.;Loadman P.;Hull M.;Knowles M. (2012) PLoS ONE. 7
-
The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE
2 -dependent cell motilityHawcroft G.;Volpato M.;Marston G.;Ingram N.;Perry S.;Cockbain A.;Race A.;Munarini A.;Belluzzi A.;Loadman P.;Coletta P.;Hull M. (2012) British Journal of Pharmacology. 166, 1724-1737.
-
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity
Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H. (2011)
-
Chromatographie analysis of polysialic acid released from neural adhesion molecule presented on glioma cell membranes
Al-Hasawi N.;Volapato M.;Loadman P. (2011) Kuwait Journal of Science and Engineering. 38, 107-130.
-
Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability
Benelkebir H.;Marie S.;Hayden A.;Lyle J.;Loadman P.;Crabb S.;Packham G.;Ganesan A. (2011) Bioorganic and Medicinal Chemistry. 19, 3650-3658.
-
Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex
Shnyder S.;Fu Y.;Habtemariam A.;Van Rijt S.;Cooper P.;Loadman P.;Sadler P. (2011) MedChemComm. 2, 666-668.
-
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.
Isambert, N.; Campone, M.; Bourbouloux, E.; Drouin, M.; Major, A.; Yin, W.; Loadman, Paul M.; Capizzi, R.; Grieshaber, C.; Fumoleau, P. (2010)
-
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases
Atkinson J.;Falconer R.;Edwards D.;Pennington C.;Siller C.;Shnyder S.;Bibby M.;Patterson L.;Loadman P.;Gill J. (2010) Cancer Research. 70, 6902-6912.
-
Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-type Matrix Metalloproteinases (MT-MMPs)
Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, D.R.; Pennington, C.J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H. (2010)
-
Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signalling in human colorectal cancer cells
Hawcroft, G.; Loadman, Paul M.; Belluzzi, A.; Hull, M.A. (2010)
-
Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells
Hawcroft G.;Loadman P.;Belluzzi A.;Hull M. (2010) Neoplasia. 12, 618-627.
-
A mathematical model of doxorubicin penetration through multicellular layers,
Evans, C.J.; Phillips, Roger M.; Jones, P.F.; Loadman, Paul M.; Sleeman, B.D.; Twelves, Christopher J.; Smye, S.W. (2009)
-
Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections
Djidja M.;Francese S.;Loadman P.;Sutton C.;Scriven P.;Claude E.;Snel M.;Franck J.;Salzet M.;Clench M. (2009) Proteomics. 9, 2750-2763.
-
Detergent addition to trypsin digest and Ion Mobility Separation prior to MS/MS improves peptide yield and Protein Identification for in situ Proteomic Investigation of Frozen and FFPE Adenocarcinoma tissue sections.
Djidja, M-C.; Francese, S.; Loadman, Paul M.; Sutton, Chris W.; Scriven, P.; Claude, E.; Snel, M.F.; Franck, J.; Salzet, M.; Clench, M.R. (2009)
-
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study.
Steward, W.P.; Middleton, M.; Benghiat, A.; Loadman, Paul M.; Hayward, C.; Walter, S.; Ford, S.; Halbert, G.; Patterson, Laurence H.; Talbot, D. (2009)
-
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts
Williams K.;Albertella M.;Fitzpatrick B.;Loadman P.;Shnyder S.;Chinje E.;Telfer B.;Dunk C.;Harris P.;Stratford I. (2009) Molecular Cancer Therapeutics. 8, 3266-3275.
-
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograft.
Williams, K.J.; Albertella, M.R.; Fitzpatrick, B.; Loadman, Paul M.; Shnyder, Steven D.; Chinje, E.C.; Telfer, B.A.; Dunk, C.R.; Harris, P.A.; Stratford, I.J. (2009)
-
Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors
Hochhauser, D.; Meyer, T.; Spanswick, V.J.; Wu, J.; Clingen, P.H.; Loadman, Paul M.; Cobb, M.; Gumbrell, L.; Begent, R.H.; Hartley, J.A.; Jodrell, D. (2009)
-
Method development for protein profiling in biological tissues by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Djidja, M-C.; Carolan, V.A.; Loadman, Paul M.; Clench, M.R. (2008)
-
Fluorescent 7-Diethylaminocoumarin Pyrrolobenzodiazepine conjugates: Synthesis, DNA-Interaction, Cytotoxicity and Differential Cellular Localization.
Wells, G.; Suggitt, Marie; Coffils, M.; Baig, M.A.H.; Howard, P.W.; Loadman, Paul M.; Hartley, J.A.; Jenkins, Terence C.; Thurston, D.E. (2008)
-
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase 1 study
Albertella, M.R.; Loadman, Paul M.; Jones, P.H.; Phillips, Roger M.; Rampling, R.; Burnet, N.; Alcock, C.; Anthoney, Alan; Vjaters, E.; Dunk, C.R.; Harris, P.A.; Wong, A.; Lalani, A.S.; Twelves, Christopher J. (2008)
-
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study
Albertella M.;Loadman P.;Jones P.;Phillips R.;Rampling R.;Burnet N.;Alcock C.;Anthoney A.;Vjaters E.;Dunk C.;Harris P.;Wong A.;Lalani A.;Twelves C. (2008) Clinical Cancer Research. 14, 1096-1104.
-
Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: Correlation of MMP-14 mRNA expression and proteolytic activity
Atkinson J.;Pennington C.;Martin S.;Anikin V.;Mearns A.;Loadman P.;Edwards D.;Gill J. (2007) European Journal of Cancer. Part A. 43, 1764-1771.
-
Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1-targeted tripartite quinone drug delivery system
Volpato, Milène; Abou-Zeid, N.; Tanner, R.W.; Glassbrook, L.T.; Taylor, James P.; Stratford, I.J.; Loadman, Paul M.; Jaffar, M.; Phillips, Roger M. (2007)
-
Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119).
Burger, A.M.; Loadman, Paul M.; Thurston, D.E.; Schultz, R.; Fiebig, H.H.; Bibby, Michael C. (2007)
-
Membrane Type MMPs Show Differential Expression in Non-Small Cell Lung Cancer (NSCLC) Compared to Normal Lung; Correlation of MMP-14 mRNA Expression and Proteolytic Activity.
Atkinson, Jennifer M.; Gill, Jason H.; Loadman, Paul M.; Martin, Sandie W.; Pennington, J.; Anikin, V.A.; Mearns, A.J.; Edwards, D.R. (2007)
-
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study
Steward W.;Middleton M.;Benghiat A.;Loadman P.;Hayward C.;Waller S.;Ford S.;Halbert G.;Patterson L.;Talbot D. (2007) Annals of Oncology. 18, 1098-1103.
-
Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry
Atkinson S.;Loadman P.;Sutton C.;Patterson L.;Clench M. (2007) Rapid Communications In Mass Spectrometry. 21, 1271-1276.
-
Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates
Wells G.;Martin C.;Howard P.;Sands Z.;Laughton C.;Tiberghien A.;Woo C.;Masterson L.;Stephenson M.;Hartley J.;Jenkins T.;Shnyder S.;Loadman P.;Waring M.;Thurston D. (2006) Journal of Medicinal Chemistry. 49, 5442-5461.
-
Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer
Puri, Rajiv; Palit, V.; Loadman, Paul M.; Flannigan, G. Michael; Shah, T.K.; Choudry, G.A.; Basu, Saurajyoti; Double, John A.; Lenaz, G.; Chawla, S.; Beer, M.; Kalken, C.V.; de Boer, R.; Beijnen, J.H.; Twelves, Christopher J.; Phillips, Roger M. (2006)
-
Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity
Volpato M.;Seargent J.;Loadman P.;Phillips R. (2005) European Journal of Cancer. Part A. 41, 1331-1338.
-
Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma
Seargent J.;Loadman P.;Martin S.;Naylor B.;Bibby M.;Gill J. (2005) Urology. 65, 815-820.
-
Pharmacological and biological evaluation of a series of substituted 1,4 naphthoquinone bioreductive drugs.
Phillips, Roger M.; Loadman, Paul M.; Maitland, Derek J.; Shnyder, Steven D.; Jaffar, M.; Steans, Gillian; Cooper, Patricia A.; Race, Amanda D.; Patterson, A.V.; Stratford, I.J. (2004)
-
NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.
Basu, Saurajyoti; Brown, John E.; Flannigan, G. Michael; Gill, Jason H.; Loadman, Paul M.; Martin, Sandie W.; Naylor, Brian; Puri, Rajiv; Scally, Andy J.; Seargent, Jill M.; Shah, Tariq K.; Phillips, Roger M. (2004)
-
Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy
Basu, Saurajyoti; Brown, John E.; Flannigan, G. Michael; Gill, Jason H.; Loadman, Paul M.; Naylor, Brian; Scally, Andy J.; Seargent, Jill M.; Shah, Tariq K.; Puri, Rajiv; Phillips, Roger M.; Martin, Sandie W. (2004)
-
Detection of (NAD(P)H:Quinone oxidoreductase-1, EC 1.6.99.2) 609C-->T and 465C-->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP.
Phillips R.;Basu S.;Brown J.;Flannigan G.;Loadman P.;Martin S.;Naylor B.;Puri R.;Shah T. (2004) International Journal of Oncology. 24, 1005-1010.
-
Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate
Kirwan, Ian G.; Loadman, Paul M.; Swaine, David J.; Anthoney, Alan; Pettit, G.R.; Lippert III, J.W.; Shnyder, Steven D.; Cooper, Patricia A.; Bibby, Michael C. (2004)
-
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
Wilkinson, Gary P.; Taylor, James P.; Shnyder, Steven D.; Loadman, Paul M.; Cooper, Patricia A.; Howard, P.W.; Thurston, D.E.; Jenkins, Terence C. (2004)
-
MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas
Gill, Jason H.; Kirwan, Ian G.; Seargent, Jill M.; Martin, Sandie W.; Tijani, S.; Anikin, V.A.; Mearns, A.J.; Bibby, Michael C.; Anthoney, Alan; Loadman, Paul M. (2004)
-
Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action.
Suggitt M.;Fearnley J.;Swaine D.;Volpato M.;Phillips R.;Bibby M.;Loadman P.;Anderson D. (2003) Teratogenesis Carcinogenesis and Mutagenesis. Suppl 2, 13-29.
-
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study
Rustin G.;Bradley C.;Galbraith S.;Stratford M.;Loadman P.;Waller S.;Bellenger K.;Gumbrell L.;Folkes L.;Halbert G. (2003) British Journal of Cancer. 88, 1160-1167.
-
Cytochrome P450 1B1 (CYP1B1) is over-expressed in human colon adeno-carcinomas relative to normal colon: Implications for drug development.
Gibson, Paul; Gill, Jason H.; Khan, Parveen A.; Seargent, Jill M.; Martin, Sandie W.; Batman, Philip A.; Griffith, John; Bradley, C.; Double, John A.; Bibby, Michael C.; Loadman, Paul M. (2003)
-
Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9
Loadman P.;Bibby M.;Phillips R. (2002) British Journal of Pharmacology. 137, 701-709.
-
A preclinical pharmacokinetic study of the bioreductive drug AQ4N
Loadman P.;Swaine D.;Bibby M.;Welham K.;Patterson L. (2001) Drug Metabolism and Disposition. 29, 422-426.
-
Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development
Phillips R.;Burger A.;Loadman P.;Jarrett C.;Swaine D.;Fiebig H. (2000) Cancer Research. 60, 6384-6390.
-
High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide
Swaine D.;Loadman P.;Bibby M.;Graham M.;Patterson L. (2000) Journal of Chromatography B: Biomedical Sciences and Applications. 742, 239-245.
-
Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
Grosios K.;Loadman P.;Swaine D.;Pettit G.;Bibby M. (2000) Anticancer Research. 20, 229-233.
-
Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice
Loadman P.;Phillips R.;Lim L.;Bibby M. (2000) Biochemical Pharmacology. 59, 831-837.
-
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1
Loadman P.;Bibby M.;Double J.;Al-Shakhaa W.;Duncan R. (1999) Clinical Cancer Research. 5, 3682-3688.
-
In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans
Calabrese C.;Loadman P.;Lim L.;Bibby M.;Double J.;Brown J.;Lamb J. (1999) Drug Metabolism and Disposition. 27, 240-245.
-
Analysis of the imidazoacridinone C1311 by high-performance liquid chromatography
Calabrese C.;Loadman P. (1997) JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS. 690, 275-281.
-
Extraction of the synthetic lytic peptide, cecropin B, from biological fluid and analysis using reversed-phase high-performance liquid chromatography
Moore A.;Loadman P.;Devine D.;Bibby M. (1995) Journal of Chromatography - Biomedical Applications. 672, 225-231.
-
Potentiation of EO9 anti-tumour activity by hydralazine
Bibby M.;Sleigh N.;Loadman P.;Double J. (1993) European Journal of Cancer. Part A. 29, 1033-1035.
-
Pre-cinical evaluation of a novel chloroethylating agent, clomesone
Matthew A.;Phillips R.;Loadman P.;Bibby M. (1993) British Journal of Cancer. 67, 441-446.
-
The relationship between the in vitro chemosensitivity of tumor cells and tumor response in vivo in an experimental tumor model
Phillips R.;Bibby M.;Double J.;Loadman P. (1991) International Journal of Cell Cloning. 9, 144-154.
-
Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy
Bibby M.;Double J.;Loadman P.;Duke C. (1989) Journal of the National Cancer Institute. 81, 216-220.
-
Factors involved in the anti-cancer activity of the investigational agents LM985 (Flavone acetic acid ester) and LM975 (flavone acetic acid)
Bibby M.;Double J.;Phillips R.;Loadman P. (1987) British Journal of Cancer. 55, 159-163.
-
Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours
Bibby M.;McDermott B.;Double J.;Phillips R.;Loadman P.;Burgess L. (1987) Cancer Chemotherapy and Pharmacology. 20, 203-206.
-
Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens
McDermott B.;Double J.;Bibby M.;Wilman D.;Loadman P.;Turner R. (1985) Journal of Chromatography - Biomedical Applications. 338, 335-345.
-
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?
Barnieh F.M.;Loadman P.M.;Falconer R.A. (2021) Biochimica et Biophysica Acta - Reviews on Cancer.
-
Progress towards a clinically-successful ATR inhibitor for cancer therapy
Barnieh F.M.;Loadman P.M.;Falconer R.A. (2021) Current Research in Pharmacology and Drug Discovery.
-
Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance
Jove M.;Spencer J.;Clench M.;Loadman P.;Twelves C. (2019) Critical Reviews in Oncology/Hematology.
-
Proteases in cancer drug delivery
Vandooren J.;Opdenakker G.;Loadman P.;Edwards D. (2016) Advanced Drug Delivery Reviews.
-
Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research
Bateson H.;Saleem S.;Loadman P.;Sutton C. (2011) Journal of Pharmacological and Toxicological Methods.
-
Separation methods for anthraquinone related anti-cancer drugs
Loadman P.;Calabrese C. (2001) Journal of Chromatography B: Biomedical Sciences and Applications.
-
Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein
Picksley S.;Dart D.;Mansoor M.;Loadman P. (2001) Expert Opinion on Therapeutic Patents.